Travere Therapeutics
Travere Therapeutics develops and delivers life-changing therapies for people living with rare diseases and recently received accelerated approval for FILSPARI® (sparsentan) for IgA nephropathy.
FILSPARI® (sparsentan) Accelerated Approval
Travere Therapeutics received accelerated approval for their product FILSPARI® (sparsentan). This approval specifically targets adults living with IgA nephropathy, a rare disease characterized by the buildup of the antibody IgA in the kidneys, which can lead to kidney damage and diseases.
Life-Changing Therapies for Rare Diseases
Travere Therapeutics focuses on developing and delivering therapies aimed at treating people with rare diseases. The company's mission revolves around addressing the needs of patients with conditions that have limited or no approved treatment options, thereby significantly impacting their quality of life.
Comprehensive Patient Support Program
Travere Therapeutics offers a comprehensive patient support program designed to assist patients through various stages of their treatment journey. This includes help with diagnosis management, insurance processing, prescription fulfillment, and treatment initiation, ensuring patients have access to their necessary medications and support.
Clinical Development in Focal Segmental Glomerulosclerosis (FSGS)
The company is engaged in late-stage clinical development for a treatment targeting focal segmental glomerulosclerosis (FSGS), a rare kidney disease currently lacking approved treatments. This effort represents a significant step forward in addressing a critical unmet medical need within the renal disease community.
Cooperative Research and Development Agreement (CRADA)
Travere Therapeutics is participating in a Cooperative Research and Development Agreement (CRADA) with agencies like the NIH and organizations such as the Alagille Syndrome Alliance. This collaboration aims to develop novel therapeutics for Alagille syndrome, emphasizing the company's commitment to advancing treatment options in rare diseases.
Support for Medical Education and Research
Travere Therapeutics provides medical education grants to support independent educational programs that are related to its therapeutic focus and products. Additionally, the company supports investigator-sponsored research, fostering a deeper understanding of its products and therapeutic areas, which can drive future innovations in treatment.
Commitment to Diversity, Equity, Inclusion, and Belonging
Travere Therapeutics is committed to diversity, equity, inclusion, and belonging across all its operations and research programs. This commitment ensures that the company fosters an inclusive environment that values diverse perspectives and promotes access and equity in its workplace and research initiatives.